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                                        Hepatocellular carcinoma (HCC) is the fifth most common cancer 
worldwide and the third most common cause of cancer mortality. 
Most HCC cases (>80%) occur in either Eastern Asia or sub-
Saharan Africa (  1  ). Most HCCs occur in men and among people 
aged 75 years and older (  1  ). Major risk factors for the development 
of HCC are chronic infection with hepatitis B virus (HBV) or 
hepatitis C virus (HCV), liver cirrhosis, exposure to aflatoxin B1, 
alcohol consumption, and diabetes. It has been estimated that 80% 
of HCC worldwide is etiologically associated with HBV (  2  ). 
  The double-stranded DNA genome of HBV contains four over-
lapping open reading frames that encode the surface protein (S), the 
core (nucleocapsid) protein core, a polymerase, and a multifunctional 
nonstructural protein called X. The PreS region (nucleotides 2854  –
  155), which consists of the PreS1 and PreS2 domains, overlaps a 
region of the polymerase gene. The enhancer II (EnhII; nucleotides 
1636  –  1744) and basal core promoter (BCP; nucleotides 1751  –  1769) 
regions overlap with the X gene (nucleotides 1374  –  1838). The pre-
core region encodes the hepatitis B e antigen (HBeAg), which is used 
clinically as an indicator of active viral replication (  3  ,  4  ). Expression of 
HBeAg and a high serum level of HBV (ie, a viral load   ≥  10    000 copies 
per milliliter) are associated with an increased risk of HCC (  5  ,  6  ). 
  Eight HBV genotypes (genotypes A  –  H) have been identiﬁ  ed 
based on a sequence divergence of greater than 8% over the entire 
HBV genome. Genotypes are further categorized into subgeno-
types based on nucleotide sequence divergence between 4% and 
8% (  7  ). Patients who are infected with HBV genotypes that have 
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     Background     The association between hepatitis B virus (HBV) mutations and hepatocarcinogenesis remains controver-
sial because of conflicting data in the literature. We conducted a meta-analysis of case  –  control and cohort 
studies to examine HBV PreS, enhancer II (EnhII), basal core promoter (BCP), and precore mutations in 
relation to the risk of hepatocellular carcinoma (HCC).   
     Methods     We searched databases for studies of these associations that were published in English or Chinese up to 
August 31, 2008. HBV mutation  –  specific odds ratios and relative risks were pooled by use of a random-
effects model and stratified by potential confounders. All statistical tests were two-sided.   
     Results     Of the 43 studies included in this meta-analysis, 40 used a case  –  control design. The 43 studies evaluated 
a total of 11    582 HBV-infected participants, of whom 2801 had HCC. Statistically significant summary odds 
ratios of HCC were obtained for any PreS mutation (3.77, 95% confidence interval [CI] = 2.57 to 5.52), 
C1653T in EnhII (2.76, 95% CI = 2.09 to 3.64), T1753V (2.35, 95% CI = 1.63 to 3.40), and A1762T/G1764A in 
BCP (3.79, 95% CI = 2.71 to 5.29). PreS mutations were more strongly associated with an increased risk of 
HCC in subjects who were infected with HBV genotype C than in those who were infected with HBV geno-
type B, whereas the opposite was true for A1762T/G1764A. C1653T, T1753V, and A1762T/G1764A were 
more strongly associated with an increased risk of HCC in hepatitis B e antigen (HBeAg)  –  positive subjects 
than in HBeAg-negative subjects. PreS mutations, C1653T, T1753V, and A1762T/G1764A accumulated 
during the progression of chronic HBV infection from the asymptomatic carrier state to HCC (  P    trend   < .001 
for each mutation). PreS mutations, C1653T, C1653T + T1753V, and A1762T/G1764A-based combinations 
of mutations had specificities greater than 80% for the prediction of HCC. The precore mutations G1896A 
and C1858T were not associated with the risk of HCC, regardless of HBeAg status and HBV genotype.   
     Conclusions     HBV PreS mutations, C1653T, T1753V, and A1762T/G1764A are associated with an increased risk of HCC. 
These mutations alone and in combination may be predictive for hepatocarcinogenesis.   
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distinct geographical distributions (ie, genotype A in Africa [A1] 
and Europe [A2], genotypes B and C in Asia, genotype D in the 
Mediterranean area and Middle East, genotype E in middle Africa, 
and genotype F in South America) differ with regard to clinical 
outcome, prognosis, and response to interferon treatment (  3  ,  7  ). 
Infection with HBV genotype C, which includes subgenotypes 
C1 and C2, is associated with increased risks of cirrhosis and HCC 
at older age compared with infection with HBV genotype B, 
whereas infection with HBV subgenotype B2 is associated with 
increased risks of HCC or of HCC recurrence in young, mostly 
noncirrhotic, patients compared with infection with HBV sub-
genotype C2 (  8    –    10  ). Although HBV subgenotypes C1 and C2 are 
associated with an increased risk of HCC, only HBV subgenotype 
C2 is independently associated with HCC (  11  ). 
  Different HBV genotypes display distinct patterns of mutations 
at the PreS region and at the EnhII, BCP, and precore (EnhII/
BCP/Precore) region in the HBV genome. Some of these muta-
tions are frequent in some genotypes or subgenotypes but not in 
others. HBV genotype  –   or HBV subgenotype  –  speciﬁ  c mutations, 
including C1653T (a C-to-T substitution at nucleotide 1653) in 
the EnhII region, T1753V (a T-to-V [C or A or G] substitution at 
nucleotide 1753), and the double mutant A1762T/G1764A (an 
A-to-T substitution at nucleotide 1762 and a G-to-A substitution 
at nucleotide 1764) in the BCP region, have been found to be 
independent risk factors for HCC (  12    –    14  ). In some studies, how-
ever, an increased risk of HCC has been shown to be associated 
with speciﬁ  c HBV mutations in the PreS and BCP regions, irre-
spective of HBV genotypes (  15    –    17  ). Deﬁ  ning the risk of HCC 
associated with speciﬁ  c HBV mutations is of public health and 
clinical importance. PreS1 and PreS2 play an essential role in the 
interaction with immune responses because they contain several 
epitopes for T or B cells. PreS mutants emerge during chronic 
HBV infections, often in patients who are treated with interferon, 
and probably represent attempts by the virus to evade host immune 
responses (  3  ). Variation and deletion in the 3  ′   terminus of PreS1 
are also associated with occult HBV infection (  18  ), which is char-
acterized by the presence of HBV DNA in serum in the absence of 
detectable hepatitis B surface antigen (HBsAg). Patients with pro-
gressive liver diseases have a higher frequency of PreS deletions 
than asymptomatic HBsAg carriers (  19  ). A1762T/G1764A and 
precore G1896A (a G-to-A substitution at nucleotide 1896) have 
been associated with active exacerbation of chronic hepatitis B, 
liver cirrhosis, and acute fulminant hepatitis (  19    –    21  ). Deﬁ  ning 
HCC-associated HBV mutations is useful for the development of 
novel HBV testing and HCC screening strategies and for optimiz-
ing HBV vaccination and antiviral treatment for the prevention of 
HCC. 
  In the past decade, numerous studies have shown that some 
mutations in the HBV PreS and EnhII/BCP/Precore regions 
are statistically signiﬁ  cantly associated with the risk of HCC. How-
ever, other studies in which the majority of patients were infected 
with HBV genotype F or C found no association between EnhII/
BCP mutations and HCC risk (  22    –    24  ). There are several reasons 
for the uncertainty as to whether these HBV mutations are genu-
ine risk factors for the development of HCC. Most of the studies 
that have investigated associations between HBV mutations and 
the risk of HCC had a small number of patients and often 
examined only speciﬁ  c viral mutations. Some studies failed to 
adjust for potential confounders, such as age, sex, and HBeAg status. 
  In this meta-analysis, we quantitatively summarized HBV 
mutations of interest in serum samples from asymptomatic HBsAg 
carriers, patients with chronic hepatitis B, patients with liver cir-
rhosis, and patients with HCC. We also stratiﬁ   ed the HBV-
infected participants into age-, sex-, HBV genotype  –  , and HBeAg 
status  –  matched groups, and then calculated the summary risk of 
HCC for these mutations. 
    Methods 
    Search Strategy and Selection Criteria 
  We searched MEDLINE (1966 to August 31, 2008), EMBASE 
(1950 to August 31, 2008), and Chinese Biological Medicine (1978 
to August 31, 2008) databases using the Medical Subject Heading 
(MeSH) terms “hepatitis B virus,” “mutation,” and “carcinoma, 
hepatocellular,” and the individual corresponding free terms. The 
Cochrane library (  http://www.cochrane.org  ) was searched with the 
term “hepatitis B virus” and “mutation.” Furthermore, we reviewed 
citations in the retrieved articles to search for additional relevant 
studies. 
  Studies were included if 1) they could be deﬁ  ned as a case  –
  control study (an incidence, prevalence, or nested case  –  control 
study) or a cohort study; 2) the diagnoses of chronic hepatitis B, 
liver cirrhosis, and HCC were according to the guidelines of the 
    CONTEXT AND CAVEATS 
    Prior knowledge 
  There are conflicting data on the association between hepatitis B 
virus (HBV) mutations and hepatocarcinogenesis.   
    Study design 
  A meta-analysis of pooled results from case  –  control and cohort 
studies that examined associations between mutation in the PreS, 
enhancer II, basal core promoter, and precore regions of HBV, and 
the risk of hepatocellular carcinoma (HCC).   
    Contribution 
  PreS mutations, C1653T, T1753V, and A1762T/G1764A were each 
associated with an increased risk of HCC and were increasingly 
more prevalent as chronic HBV infection progressed from the 
asymptomatic hepatitis B surface antigen carrier state to liver cir-
rhosis or HCC. Most of these mutations, alone and in combination, 
were more than 80% specific for the prediction of HCC.   
    Implications 
  Frequent examination of patients with chronic HBV infections for 
the presence of PreS mutations, C1653T, T1753V, and A1762T/
G1764A may be useful for identifying which patients require pre-
ventive antiviral treatment and for the prediction of HCC.   
    Limitations 
  HBV mutation data were not available for all participants. The find-
ings may not be generalizable to populations that are infected with 
HBV genotypes other than C or B. Only studies published in English 
or Chinese were included. 
  From the Editors     
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American Association for the Study of Liver Diseases (  25  ,  26  ); 
3) the exposure of interest was HBV mutations; 4) the outcome of 
interest was HCC; and 5) odds ratios (ORs) in case  –  control studies 
or relative risks in cohort studies were reported with the 95% 
conﬁ  dence intervals (CIs) (or, if 95% CIs were not reported, the 
reported data were sufﬁ  cient to calculate them). We excluded stud-
ies that were not published as full reports; studies that included 
fewer than 10 participants; studies without control subjects; and 
studies that included patients who were coinfected with HCV or 
hepatitis D virus (HDV), had alcohol-related liver diseases, or had 
previously received antiviral treatments. If the duration and 
sources of study population recruitment overlapped by more than 
30% in two or more papers by the same authors, we only included 
the most recent study or the study with the larger number of par-
ticipants. We included separate studies that included participants 
from the same source if the earlier paper focused on a given muta-
tion and the subsequent paper(s) examined additional mutations or 
the study design and the numbers of participants were different 
from each other.   
    Data Extraction 
  Data were independently extracted by two investigators (S. Liu 
and H. Zhang) and checked by the other authors. The concor-
dance rate between the two investigators was 90.3%. Discrepancies 
were resolved by consensus. The following information was 
abstracted from all included publications: study design, year, coun-
try or area, number of included patients, mutation sites, HBV 
genotype(s), mutation detection method, and potential confound-
ers. Data were extracted only for participants whose mutation 
status had been determined. In our evaluation of PreS mutations, 
deletions and point mutations in PreS1 and/or PreS2 that were 
predicted or known to decrease PreS or S expression were 
included; patients who were coinfected with viruses that contained 
both wild-type PreS and PreS mutants were not included. To 
investigate if there are specific PreS mutations (deletion or point 
mutations) that were associated with an increased risk of HCC, we 
extracted the sequences and compared the frequencies of deleted 
portions in the PreS region between HBV-infected patients with 
and without HCC from the included studies. We also evaluated 
the frequencies of point mutations at the promoter sites of PreS1 
and PreS2 using data from the HBV-infected patients with and 
without HCC. In our evaluation of the BCP A1762T/G1764A 
double mutant, subjects with either single mutation or a deletion 
at either site were not included in the analysis. HBV sequences 
reported in the included studies were retrieved from the GenBank 
database and aligned by using the basic local alignment search tool 
(BLAST;   http://www.ncbi.nih.gov/BLAST  ).   
    Assessment of Study Quality 
  Two investigators (S. Liu and H. Zhang) independently rated the 
quality of each retrieved study by using a 12-point scoring system 
that was developed for this meta-analysis. The scoring system was 
based on factors that we thought would be indicators of good qual-
ity observational studies (  Table 1  ). Study design, case number, 
source of population, mutation detection method, and matching of 
case and control subjects were included in our evaluation of the 
quality of an included study. Studies were assigned a score of 2 for 
each for the following quality parameters: a prospec  tive design, 
more than 100 case subjects, inclusion of community-based par-
ticipants, use of DNA sequenc  ing as the method for detecting 
HBV mutations, matching for age and sex, and matching for 
HBeAg status and HBV genotype. Studies that received an overall 
score of 8 or higher were classified as high-quality studies, those 
with an overall score of 5  –  7 were classified as medium-quality 
studies, and those with an overall score of 4 or lower were consid-
ered low-quality studies for the purpose of this analysis. These cut 
points were chosen according to the distribution of relative quality 
scores of all included studies. At least 700 (25%) of the pooled 
patients with HCC were chosen for the number of case patients in 
each of the three categories. The Spearman rank correlation coef-
ficient for agreement between the two raters on overall quality 
rating for all included studies was .96. Disagreements were 
resolved by consensus.           
    Statistical Analysis 
  The effect measures of interest were odds ratios for case  –  control 
studies, relative risks for cohort studies, and the corresponding 
95% confidence intervals. Statistical heterogeneity among studies 
  Table 1    .       Quality criteria for the included studies  *     
    Quality parameter
Score 
  21 0    
    Study design Cohort study or nested 
 case  –  control study
Incidence case  –  control study. 
 Prevalence  case  –  control study
  —   
  No. of case subjects >100 50  –  100 <50 
  Source of population Community-based or 
  from two or more countries
  ≥  2 hospitals 1 hospital 
  Mutation detection method DNA sequencing Line probe assay 
  (eg, INNO-LiPA, OLA)
RFLP, PAGE, self-made 
  chips, microwell hybridization, 
  or direct electrophoresis 
  Matching of case and control subjects 
         Confounder group 1 Age and sex Age or sex None 
         Confounder group 2 HBeAg status and 
 HBV  genotype
HBeAg status or 
 HBV  genotype
None   
    *       —   = designs other than cohort or nested, incidence, or prevalence case  –  control not included in meta-analysis; INNO-LiPA = Innogenetics line probe assay; 
OLA = oligonucleotide ligation assay; RFLP = restriction fragment length polymorphism; PAGE = polyacrylamide gel electrophoresis; HBeAg = hepatitis B e 
antigen; HBV = hepatitis B virus.     jnci.oxfordjournals.org    JNCI | Articles 1069
was evaluated using the      
2   test,   P   values, and   I   
2   statistics (  27  ). A 
random-effects model was used to obtain summary odds ratios or 
relative risks. We conducted a sensitivity analysis in which one 
study was removed and the rest were analyzed to evaluate whether 
the results were affected statistically significantly. Publication bias 
was evaluated by using funnel plots and the Egger test (  28  ). A 
  P   value less than .1 was considered to indicate statistically signifi-
cant publication bias. We stratified the HBV-infected participants 
into age-, sex-, HBV genotype  –  , and HBeAg status  –  matched 
groups and then calculated the summary risk of HCC for HBV 
mutations. We also conducted analyses by grouping the control 
subjects according to stages (asymptomatic HBsAg carrier states, 
chronic hepatitis B, and liver cirrhosis) of chronic HBV infection; 
the meta-analyses were performed using Review Manager version 
5.0 (The Nordic Cochrane Centre, The Cochrane Collaboration, 
Copenhagen, Denmark). Summary estimates of HCC for PreS 
mutations, C1653T, T1753V, A1762T/G1764A, G1896A, and 
C1858T (a C-to-T substitution at nucleotide 1858) for patients 
with HCC were calculated with the use of Stata software (version 
9.1; Stata Corp, College Station, TX). The       2   test was used to 
examine differences in categorical variables, such as the frequen-
cies of HBV mutations between subjects with and without HCC. 
A   P   value less than .05 was considered statistically significant. Epi 
Info software (version 3.3.2;   http://www.cdc.gov/epiinfo/epiinfo.
htm  ) from the Centers for Disease Control and Prevention 
(Atlanta, GA) was used for the analysis of linear trends in propor-
tions of HBV mutations during the progression of HBV chronic 
infections. To calculate the sensitivity and the specificity of single 
mutation and combined mutations for HCC, 2 × 2 tables were 
generated by using the pooled data for HCC and non-HCC sub-
jects with and without a specific HBV mutation or combined 
mutations. The sensitivity was calculated as the ratio of HCC 
patients with the specific HBV mutation(s) to the HCC patients 
with and without the mutation(s); the specificity was calculated as 
the ratio of the non-HCC patients (or participants) without the 
specific HBV mutation(s) to the non-HCC patients (or partici-
pants) with and without the mutation(s). All statistical tests were 
two-sided.     
    Results 
  We identified 1258 potentially relevant articles from our search 
of the published literature. We excluded 1215 articles, resulting 
in 43 articles for analysis (  Figure 1  ). Of the 43 included studies, 
13 were from Mainland China (  13  ,  29    –    40  ), four were from Japan 
(41  –  44), seven were from Taiwan (  15    –    17  ,  45    –    48  ), three were 
from the United States (  22  ,  49  ,  50  ), four were from Korea (  51    –
    54  ), two were from Hong Kong (  14  ,  55  ), two were from Gambia 
(  56  ,  57  ), one each were from Vietnam (  58  ) and South Africa (  59  ), 
and six were from two or more   countries or regions       (  12  ,  23  ,
  60    –    63  ). We found no related or relevant meta-analyses in the 
Cochrane library. A summary of the 43 included studies is given 
in   Table 2  . These studies included 11    582 HBV-infected par-
ticipants, of whom 2801 had HCC. The most commonly 
reported HBV mutations associated with HCC risk were PreS 
mutations, A1762T/G1764A, G1896A, T1753V, C1653T, and 
C1858T.               
  The risk estimates of HCC for PreS mutations, C1653T, 
T1753V, A1762T/G1764A, G1896A, and C1858T in individual 
case  –  control and cohort studies and summary estimates are shown 
in   Figure 2  . Overall, we observed statistically signiﬁ  cant associations 
between PreS mutations (summary OR = 3.77, 95% CI = 2.57 to 
5.52), C1653T (summary OR = 2.76, 95% CI = 2.09 to 3.64), 
T1753V (summary OR = 2.35, 95% CI = 1.63 to 3.40), and 
A1762T/G1764A (summary OR = 3.79, 95% CI = 2.71 to 5.29), and 
the risk of HCC in both case  –  control and cohort studies. However, 
C1858T and G1896A were not statistically signiﬁ  cantly associated 
with HCC risk. Statistically signiﬁ  cant heterogeneity was found 
among studies of PreS mutations, T1753V, A1762T/G1764A, 
C1858T, and G1896A. When we excluded the publication(s) with 
statistically signiﬁ  cant heterogeneity and repeated the analysis, the 
summary estimates for PreS mutations, T1753V, A1762T/G1764A, 
C1858T, and G1896A did not change statistically signiﬁ  cantly. 
Egger  ’  s test suggested no statistically signiﬁ  cant publication bias for 
the studies of C1653T, T1753V, A1762T/G1764A, C1858T, and 
G1896A. However, statistically signiﬁ   cant publication bias was 
found in the studies of PreS mutations (Egger test   t   value = 3.47, 
95% CI = 1.29 to 6.80,   P   = .01). The funnel plot for the studies of 
PreS mutations showed an asymmetrical distribution of the studies 
(  Figure 3  ),   indicating   publication bias      .                 
  We extracted adjusted odds ratios and relative risks from the 
included studies. The summary adjusted odds ratio for PreS muta-
tions from four studies (  16  ,  33  ,  43  ,  45  ) was 6.18 (95% CI = 2.63 to 
14.47), for C1653T from ﬁ  ve studies (  12  ,  23  ,  35  ,  42  ,  60  ) was 3.45 
(95% CI = 1.12 to 10.65), for T1753V from six studies 
(  12  ,  23  ,  35  ,  42  ,  46  ,  60  ) was 2.56 (95% CI = 1.05 to 6.22), for A1762T/
G1764A from 11 studies (  12  ,  15  ,  17  ,  23  ,  35  ,  42  ,  45  ,  46  ,  50  ,  55  ,  60  ) was 
4.87 (95% CI = 2.21 to 10.70), and for G1896A from nine studies 
(  12  ,  17  ,  23  ,  35  ,  42  ,  45  ,  46  ,  50  ,  60  ) was 1.21 (95% CI = 0.72 to 2.03) 
(  Supplementary Figure 1  , available online). The summary adjusted 
relative risks for A1762T/G1764A and G1896A from two cohort 
studies (  48  ,  49  ) were 1.93 (95% CI = 1.27 to 2.92) and 1.12 (95% 
 
1535 citations identified by search
277 duplicate studies 
1011 articles excluded after title review 
302 not relevant to HBV mutation or HCC
187 TP53 gene mutation and HBV 
144 associated with antivirus treatment 
378 associated with HCV 
247 abstracts retrieved 
175 articles excluded after abstract review  
117 not relevant to HBV mutations 
58 not relevant to HCC 
72 full manuscripts retrieved
29 articles excluded after review of full text 
19 lacked control data
2 participants coinfected with HCV or HDV
3 authors published 2 related papers 
5 small sample size  
43 studies included in meta-analysis 
1258 potentially relevant citations identified
 
    Figure 1    .       Flow chart of article selection. HBV = hepatitis B virus; HCC = 
hepatocellular carcinoma; HCV = hepatitis C virus; HDV = hepatitis D virus.         1070   Articles | JNCI  Vol. 101, Issue 15  |  August 5, 2009
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Odds ratio
.5 1 2 4 8 16 32 64
Study, first author, year (reference) OR (95% CI) Weight (%)
Blackberg, 2003 (62) 8.25 (1.79 to 38.01) 5.0 
Chen, 2006 (45) 2.60 (1.29 to 5.23) 13.2 
Choi, 2007 (51) 2.62 (1.50 to 4.60) 15.7 
Gao, 2007 (33) 21.90 (6.53 to 73.47) 7.0 
Lin, 2007 (16) 2.99 (1.51 to 5.90) 13.5 
Sugauchi, 2003 (43) 3.58 ( 1.44 to 8.89) 10.1 
Huy, 2003 (63) 2.66 (1.36 to 5.20) 13.7 
Mun, 2008 (54) 2.63 (1.17 to 5.89) 11.5 
Cao, 2008 (29) 7.44  3.03 to 18.29) 10.3 
Overall 3.77 (2.57 to 5.52) 100.0 
Odds ratio
.25 .5 1 2 4 8 16 32 64
Ito, 2006 (60) 5.44 (2.38 to 12.46) 8.6 
Shinkai, 2007 (42) 3.00 (1.56 to 5.75) 12.2 
Takahashi, 1999 (44) 3.43 (1.87 to 6.27) 13.4 
Tanaka, 2006 (12) 1.99 (1.24 to 3.20)  17.8
Truong, 2007 (23) 1.62 (0.58 to 4.50)  6.1 
Wang, 2007 (35) 12.71 (3.28 to 49.21)  3.8
Yuen, 2008 (55) 2.43 (1.08 to 5.45) 8.9 
Kim, 2008 (53) 2.93 (1.47 to 5.82) 11.3 
Sakamoto, 2006 (61) 3.08 (1.00 to 9.46) 5.3 
Yuan, 2007 (13) 1.85 (0.32 to 10.66) 2.4 
Guo, 2008 (34) 1.56 (0.74 to 3.27) 10.2 
Overall 2.76 (2.09 to 3.64) 100.0 
Study, first author, year (reference) OR (95% CI) Weight (%)
Odds ratio
.25 .5 1 2 4 8 16 32
NCC
Chou, 2008 (46) 2.43 (1.33 to 4.44) 10.0 
Guo, 2008 (34) 1.90 (0.80 to 4.55) 7.7 
Subtotal 2.25 (1.37 to 3.69) 17.7 
PCC or ICC
Blackberg, 2003 (62) 1.30 (0.32 to 5.27) 4.6 
Ito, 2006 (60) 1.16 (0.46 to 2.92) 7.3 
Kim, 2008 (53) 2.41 (1.21 to 4.80) 9.2 
Shinkai, 2007 (42) 3.21 (1.63 to 6.31) 9.3 
Takahashi, 1999 (44) 3.44 (1.84 to 6.43) 9.8 
Tanaka, 2006 (12) 2.53 (1.61 to 3.98) 11.3 
Truong, 2007 (23) 1.42 (0.56 to 3.58) 7.3 
Wang, 2007 (35) 8.67 (4.11 to 18.29) 8.7 
Yuan, 2007 (13) 6.53 (1.36 to 31.23) 3.9 
Yuen, 2008 (55) 0.91 (0.54 to 1.54) 10.7 
Subtotal 2.40 (1.53 to 3.75) 82.3 
Overall 2.35 (1.63 to 3.40) 100.0 
A
B
C
Study, first author, year (reference) OR (95% CI) Weight (%)
PreS
T1753V
C1653T
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.125 .25 .5 1 2 4 8 16 32
Fang, 2002 (32) 0.38 (0.16 to 0.85) 21.8 
Sakamoto, 2006 (61) 2.36 (0.98 to 5.68) 21.4 
Truong, 2007 (23) 2.02 (0.58 to 7.03) 18.7 
Wang, 2007 (35) 0.33 (0.17 to 0.64) 22.8 
Yuan, 2007 (13) 6.32 (1.16 to 34.26) 15.3 
Overall 1.14 (0.39 to 3.29) 100.0 
E 
Study, first author, year (reference) OR (95% CI) Weight (%)
Odds ratio 
 .5 1 2 4 8  16  32  64  128  256
 NCC
 Chou, 2008 (46) 2.74 (1.74 to 4.30)   4.0 
 Guo, 2008 (34) 0.69 (0.33 to 1.48)   3.6
 Kao, 2003 (15) 9.07 (4.98 to 16.53)   3.8
 Zhang, 2007 (36) 1.48 (0.54 to 4.08)   3.1 
 Zhu, 2008 (40) 16.04 (2.05 to 125.47)   1.6
Subtotal 2.92 (1.09 to 7.80)  16.2 
 PCC or ICC
 Baptista, 1999 (59) 16.31 (5.45 to 48.81)   3.0 
 Blackberg, 2003 (62) 1.43 (0.38 to 5.44)   2.6 
 Chen, 2006 (45) 3.04 (1.43 to 6.49)   3.6
 Deng, 2004 (30) 4.30 (1.87 to 9.87)   3.4
 Ding, 2006 (31) 4.15 (1.52 to 11.37)   3.1
 Fang, 2002 (32) 38.80 (5.11 to 294.67)   1.7
 Ito, 2006 (60) 2.61 (0.82 to 8.32)   2.9
 Kim, 2008 (53) 4.85 (2.13 to 11.07)   3.4 
 Laskus, 1998 (56) 1.88 (0.67 to 5.31)   3.1
 Liu, 2006 (17) 19.67 (11.33 to 34.13)   3.9
 Livingston, 2007 (22) 1.31 (0.57 to 3.04)   3.4 
 Mendy, 2008 (57) 1.50 (0.76 to 2.94)   3.7
 Muroyama, 2006 (41) 0.80 (0.26 to 2.45)   2.9 
 Sakamoto, 2006 (61) 14.00 (5.01 to 39.16)   3.1
 Shinkai, 2007 (42) 3.96 (1.58 to 9.90)   3.3
 Song, 2005 (58) 15.07 (0.79 to 286.51)   1.0 
 Sung, 2008 (14) 5.65 (2.10 to 15.23)   3.2 
 Takahashi, 1999 (44) 5.26 (2.29 to 12.09)   3.4
 Tanaka, 2006 (12) 3.26 (1.68 to 6.33)   3.7 
 Tong, 2007 (50) 12.86 (5.49 to 30.11)   3.4 
 Truong, 2007 (23) 1.42 (0.54 to 3.69)   3.2
 Wang, 2007 (35) 9.40 (3.97 to 22.28)   3.4 
 Yuan, 2007 (13) 5.91 (0.68 to 51.06)   1.6 
 Yuen, 2008 (55) 4.09 (2.41 to 6.95)   3.9
 Zhang, 2006 (37) 0.98 (0.40 to 2.39)   3.3
 Zhang, 2007 (38) 4.38 (1.58 to 12.13)   3.1 
 Zhou, 2007 (39) 2.15 (0.95 to 4.87)   3.5
 Subtotal 4.00 (2.79 to 5.72)  83.8 
3.79 (2.71 to 5.29)  100.0 
RR/OR of HCC for A1762T/G1764A
 Summary estimate
 Tong, 2006 (49) 2.02 (1.44 to 2.84)   23.8
 Jang, 2007 (52) 1.39 (0.84 to 2.30)   10.7
 Yang, 2008 (48) 1.78 (1.45 to 2.19)   65.5
 Summary estimate 1.79 (1.51 to 2.11)   100.0
 Cohort study, first author, year (reference)  RR (95% CI)  Weight (%)
D
 Weight (%) OR (95% CI)  Case-control study, first author, year (reference)
A1762T/G1764A
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 .125  .25  .5 1 2 4 8 16
NCC
Chou, 2008 (46) 0.75 (0.48 to 1.17) 6.4 
 Kao, 2003 (15) 0.86 (0.45 to 1.62) 5.7 
Subtotal 0.78 (0.55 to 1.13) 12.1 
PCC or ICC
Blackberg, 2003 (62) 0.86 (0.23 to 3.29) 3.3 
Chen, 2006 (45) 3.16 (1.43 to 7.00)  5.1
Fang, 2002 (32) 1.39 (0.58 to 3.34) 4.8 
Ito, 2006 (60) 0.95 (0.43 to 2.08) 5.1 
Laskus, 1998 (56) 1.88 (0.67 to 5.31) 4.2 
Liu, 2006 (17) 5.16 (3.24 to 8.21) 6.3 
Livingston, 2007 (22) 0.62 (0.26 to 1.51) 4.7 
Mendy, 2008 (57) 1.12 (0.59 to 2.12) 5.7 
Muroyama, 2006 (41) 1.62 (0.65 to 4.03) 4.6 
Ni, 2003 (47) 1.28 (0.31 to 5.25) 3.1 
Shinkai, 2007 (42) 1.11 (0.59  to 2.06) 5.8 
Tanaka, 2006 (12) 0.53 (0.33 to 0.84) 6.4 
Tong, 2007 (50) 1.97 (1.01 to 3.84) 5.6 
Truong, 2007 (23) 0.49 (0.17 to 1.43) 4.1 
Wang, 2007 (35) 1.65 (0.83 to 3.28) 5.5 
Yuen, 2008 (55) 0.71 (0.48 to 1.04) 6.6 
Sakamoto, 2006 (61) 1.12 (0.10 to 12.80)  1.4 
Yuan, 2007 (13) 0.90 (0.16 to 4.90)  2.4
Zhou, 2007 (39) 0.55 (0.14 to 2.16) 3.2 
Subtotal 1.21 (0.84 to 1.74) 87.9 
Summary estimate 1.15 (0.83 to 1.60)  100.0
Jang, 2007 (52) 0.38 (0.02 to 6.25) 15.3
Tong, 2006 (49) 1.70 (1.11 to 2.60) 42.1
Yang, 2008 (48) 0.40 (0.28 to 0.58) 42.6
Summary estimate 0.73 (0.19 to 2.85) 100.0 
Cohort Study, first author, year (reference) RR (95% CI) Weight (%)
F
Case-control Study, first author, year (reference) OR (95% CI) Weight (%)
RR/OR of HCC for G1896A
G1896A
    Figure 2    .       Summary odds ratios (ORs; in case  –  control studies) or relative 
risks (RRs; in cohort studies) of hepatocellular carcinoma (HCC) for PreS 
  (A)  , C1653T   (B)  , T1753V   (C)  , A1762T/G1764A   (D)  , C1858T   (E)  , and 
G1896A   (F)   mutations.   Squares   represent study-speciﬁ  c estimates (  size 
of the square   reﬂ  ects the study-speciﬁ  c statistical weight);   horizontal 
lines   represent 95% conﬁ   dence intervals (CIs);   diamonds   represent 
summary estimates with corresponding 95% CIs. Test for heterogene-
ity:   (A)     P   = .045,   I   
2   = 49.3%;   (B)     P   = .197,   I   
2   = 25.9%;   (C)     P   < .001,   I   
2   = 
66.3%;   (D)     P   < .001,   I   
2   = 76.4%;   (E)     P   < .001,   I   
2   = 83.2%;   (F)     P   < .001,   I   
2   = 
80.0%. A random-effects model was used for all analyses. All statistical 
tests were two-sided. NCC = nested case –  control; PCC = prevalence case –
  control; ICC = incidence case  –  control.         
CI = 0.09 to 13.16), respectively (  Supplementary Figure 2  , avail-
able online). 
  We next evaluated the summary crude odds ratios of HCC for 
HBV mutations among case and control subjects who were 
matched by age; age and sex; age, sex, and HBeAg status; and age, 
sex, HBeAg status, and HBV genotype. The summary odds ratios 
of HCC for T1753V and A1762T/G1764A were higher for the 
unmatched groups than for any of the matched groups (  Table 3  ). 
We evaluated the summary odds ratios for HBV mutations strati-
ﬁ   ed by HBV genotypes and subgenotypes, study location, and 
HBeAg status. The summary odds ratio for PreS mutations was 
higher in subjects with HBV genotype C than in those with HBV 
genotype B, whereas the opposite was true for A1762T/G1764A, 
even though both PreS mutations and A1762T/G1764A were 
statistically signiﬁ  cantly associated with the risk of HCC in both 
HBV genotypes. C1653T in HBV subgenotype C2 and T1753V 
and A1762T/G1764A in HBV subgenotypes C1 and C2 were sta-
tistically signiﬁ  cantly associated with an increased risk of HCC. 
The statistically signiﬁ  cant summary odds ratios for PreS muta-
tions, C1653T, T1753V, and A1762T/G1764A were essentially 
unchanged when we stratiﬁ  ed the participants by study location 
(ie, China, Taiwan, or Hong Kong, Japan, or Korea). The sum-
mary odds ratio for PreS mutations was higher in the China, 
Taiwan, and Hong Kong group than in groups from other areas. 
A statistically signiﬁ  cant summary odds ratio for A1762T/G1764A 
was also found for subjects from areas other than Asia. The sum-
mary odds ratios for C1653T, T1753V, and A1762T/G1764A in 
the HBeAg-positive group were higher than the corresponding 
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estimates in the HBeAg-negative group. The summary odds ratios 
for C1653T, T1753V, and A1762T/G1764A increased with 
decreasing study quality score, whereas the summary odds ratios 
for PreS mutations decreased with decreasing study quality score. 
These results are summarized in   Table 3  . G1896A and C1858T 
were not associated with the risk of HCC, regardless of HBeAg 
status and HBV genotype (data not shown).         
  We next investigated if speciﬁ  c PreS mutations (deletions and 
point mutations) were associated with an increased risk of HCC. 
First, we obtained data on 142 PreS deletions from 102 HBV-
infected patients (57 with HCC and 45 without HCC) from the 
included papers (  33  ,  45  ,  54  ,  62  ). In the reported deletion region 
(nucleotides 2842  –  104) of PreS, the 5  ′  -terminal half (nucleotides 
3206  –  60) was the most frequently deleted portion of the PreS 
region in the patients with and without HCC. The frequencies of 
PreS deletion in this region (nucleotides 3206  –  60) were 43.0% in 
the patients with HCC and 28.6% in the patients without HCC. 
The difference in the frequency of 5  ′  -terminal half deletions 
between patients with and without HCC was not statistically sig-
niﬁ  cant (  P   = .075). Second, we obtained data for PreS1 promoter 
mutations from 199 patients (66 with HCC and 133 without 
HCC) and PreS2 promoter mutations from 496 patients (157 with 
HCC and 339 without HCC) from the included studies 
(  29  ,  33  ,  51  ,  54  ,  62  ). The frequencies of mutations at the PreS1 and 
PreS2 promoters were statistically signiﬁ   cantly higher in the 
patients with HCC than in the patients without HCC (PreS1 
promoter mutation: 19.7% vs 3.0%,   P   < .001; PreS2 promoter 
mutation: 15.3% vs 8.9%,   P   = .032). 
  To examine the associations between HBV mutations and the 
risk of HCC during the progression of HBV chronic infection, we 
grouped the control subjects into three groups  —  asymptomatic 
HBsAg carriers, patients with chronic hepatitis B, and patients 
with liver cirrhosis  —  and evaluated the summary risk estimates for 
PreS mutations, C1653T, T1753V, and A1762T/G1764A in each 
group. The summary odds ratios of HCC for PreS mutations, 
C1653T, T1753V, and A1762T/G1764A decreased successively 
when we used asymptomatic HBsAg carriers, patients with chronic 
hepatitis B, or patients with liver cirrhosis as control subjects (data 
not shown). We then summarized the frequencies of PreS muta-
tions, C1653T, T1753V, and A1762T/G1764A in asymptomatic 
HBsAg carriers, patients with chronic hepatitis B, and patients 
with liver cirrhosis from all included studies. The frequency of 
each mutation increased successively from the asymptomatic 
HBsAg carrier state to chronic hepatitis B to liver cirrhosis, the 
three major steps of HBV-induced carcinogenesis (  P    trend   < .001 for 
each mutation) (  Figure 4  ). Thus, PreS mutations, C1653T, 
T1753V, and A1762T/G1764A accumulate during the progres-
sion of chronic HBV infection.         
  To examine the potential value of the presence of HBV muta-
tions, either alone or in combination, for the prediction of HCC, 
we ﬁ  rst retrieved the 169 available HBV sequences from GenBank 
[accession numbers AB241109  –  AB241117 (  61  ) and AB307808  –
  AB307967 (  42  )] and aligned them online to obtain data for HBV 
mutations that occur in combination. We also extracted data for 
HBV mutations in combination from the included studies 
(  13  ,  32  ,  41  ,  44  ,  45  ,  50  ,  59  ) for the analysis of A1762T/G1764A-based 
combinations of HBV mutations. Of these mutation data, 220 
were from the patients with HCC, 149 from the patients with 
chronic hepatitis B, 58 from the patients with liver cirrhosis, and 
164 from asymptomatic HBsAg carriers. We found that the fre-
quencies of A1762T/G1764A + C1653T (8.6%), A1762T/G1764A + 
T1753V (14.6%), A1762T/G1764A + PreS mutation (2.2%), and 
A1762T/G1764A + C1653T + T1753V (3.2%) were low 
in asymptomatic HBsAg carriers. The frequencies of A1762T/
G1764A-based combined mutations were statistically signiﬁ  cantly 
higher in patients with HCC than in patients without HCC 
(A1762T/G1764A + C1653T: 43.4% vs 15.8%,   P   < .001; A1762T/
G1764A + T1753V: 51.7% vs 19.6%,   P   < .001; A1762T/G1764A + 
PreS mutation: 43.6% vs 20.8%,   P   = .002; and A1762T/G1764A + 
C1653T + T1753V: 24.3% vs 6.1%,   P   < .001). Finally, we evalu-
ated the frequencies of PreS mutations, C1653T, T1753V, and 
A1762T/G1764A alone and in combinations using data extracted 
from all included studies as potential biomarkers for the prediction 
of HCC. A1762T/G1764A had a sensitivity and speciﬁ  city  of 
70.6% (95% CI = 68.7% to 72.5%) and 60.6% (95% CI = 68.7% 
to 62.0%), respectively, whereas C1653T + T1753V and A1762T/
G1764A + C1653T + T1753V had high speciﬁ  city (92.6% [95% 
CI = 89.2% to 96.0%] and 93.9% [95% CI = 90.5% to 97.2%], 
respectively) but low sensitivity (20.6% [95% CI = 14.9% to 
26.3%] and 24.3% [95% CI = 17.5% to 31.1%], respectively) 
(  Table 4  ).           
    Discussion 
  This meta-analysis shows that PreS mutations, C1653T, T1753V, 
and A1762T/G1764A are each associated with a statistically sig-
nificantly increased risk of HCC. Using the pooled crude odds 
ratios from the included studies, we found that PreS mutations 
were associated with 3.77-fold increased risk of HCC, C1653T 
with a 2.76-fold increased risk, T1753V with a 2.35-fold increased 
risk, and A1762T/G1764A with a 3.79-fold increased risk of 
HCC compared with HBV without mutations. The results were 
similar when we used pooled adjusted odds ratios. The relative 
strength of the association between HCC risk and PreS muta-
tions or A1762T/G1764A was higher than that between HCC 
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risk and C1653T or T1753V. G1896A and C1858T were not 
statistically significantly associated with HCC risk. Results from 
the pooled cohort studies were consistent with those from the 
pooled case  –  control studies. 
  Age, sex, HBV genotype, and HBeAg status have been shown 
to be associated with the development of HBV-related HCC 
(  1  ,  2  ,  5    –    11  ). We extracted data on these potential confounders 
where possible from the included studies and evaluated the associa-
tion between HBV mutations and HCC risk in confounder-
matched groups of subjects with and without HCC (  Table 3  ). Our 
ﬁ  nding that the summary odds ratios for T1753V and A1762T/
G1764A were higher in the confounder-unmatched, low-quality 
studies than in the confounder-matched, high-quality studies sug-
gests that potential confounders play an important role in evaluat-
ing HBV mutations and risk of HCC. In hospital-based studies 
[eg, (  10  )], we found that average age of the patients with chronic 
    Figure 4    .        Frequencies of PreS, C1653T, 
T1753V, or A1762T/G1764A mutations 
among asymptomatic hepatitis B surface 
antigen carriers (ASC), patients with chronic 
hepatitis B (CHB), patients with liver cirrho-
sis (LC), and patients with hepatocellular 
carcinoma (HCC) from the pooled data. 
  P   values (two-sided) are from the       2   test. 
Absolute numbers of the participants with 
hepatitis B virus mutation data are shown 
on the top of each column. The   numerators   
represent the number of the patients (par-
ticipants) with the mutation(s). The   denom-
inators   represent subtotal number of the 
patients (participants) with and without the 
mutation(s).         
  Table 4    .       Sensitivity and specificity of single and combined mutations of hepatitis B virus for the prediction of hepatocellular 
carcinoma  *     
    Mutation status No. of HCC patients No. of patients without HCC    †    Sensitivity, % (95% CI) Specificity, % (95% CI)   
    PreS    ‡     
         Positive 187 219 48.2 (43.2 to 53.2) 80.7 (78.4 to 83.0) 
         Negative 201 915   
  C1653T    ‡     
         Positive 257 225 40.0 (33.4 to 40.1) 81.9 (79.8 to 84.0) 
         Negative 438 1018   
  T1753V    ‡     
         Positive 317 284 39.0 (35.7 to 42.4) 79.7 (77.6 to 81.8) 
         Negative 495 1113   
  A1762T/G1764A    ‡     
         Positive 1566 1861 70.6 (68.7 to 72.5) 60.6 (59.2 to 62.0) 
         Negative 651 2863   
  C1653T + T1753V 
         Positive 40 17 20.6 (14.9 to 26.3) 92.6 (89.2 to 96.0) 
         Negative 154 212   
  A1762T/G1764A + PreS 
         Positive 24 22 43.6 (30.5 to 56.7) 79.2 (71.5 to 87.0) 
         Negative 31 84   
  A1762T/G1764A + C1653T 
         Positive 66 31 43.4 (35.5 to 51.3) 84.2 (79.1 to 89.3) 
         Negative 86 165   
  A1762T/G1764A + T1753V 
         Positive 106 62 51.7 (44.9 to 58.5) 80.4 (76.1 to 84.8) 
         Negative 99 255   
  A1762T/G1764A + C1653T + T1753V 
         Positive 37 12 24.3 (17.5 to 31.1) 93.9 (90.5 to 97.2) 
         Negative 115 184     
    *     Data extracted from all included studies. CI    =    confidence interval; HCC    =    hepatocellular carcinoma.   
      †       Includes asymptomatic hepatitis B surface antigen carriers, and patients with chronic hepatitis B or liver cirrhosis, and unclassified hepatitis B virus  –  infected 
participants without HCC.   
      ‡       Includes the indicated mutation alone and in combination with other mutations.     jnci.oxfordjournals.org    JNCI | Articles 1079
hepatitis B was 10 years younger than that of the patients with 
HCC, whereas the male to female ratio in the patients with HCC 
was statistically signiﬁ  cantly higher than that in the patients with 
chronic hepatitis B and in the asymptomatic HBsAg carriers. 
Moreover, HBV mutations, including A1762T/G1764A, accumu-
late with increasing age (  48  ). The association between HBV muta-
tions and HCC risk is therefore more likely to be overestimated in 
the confounder-unmatched, low-quality studies than in the age- 
and sex-matched, high-quality studies. 
  Because mutations at the EnhII/BCP/Precore region might 
decrease HBsAg expression (  3  ), we investigated the summary odds 
ratios of HCC for C1653T, T1753V, G1896A, and A1762T/
G1764A in groups that differed by HBeAg status. The summary 
odds ratios for C1653T, T1753V, and A1762T/G1764A were 
higher in the HBeAg-positive group than in the HBeAg-negative 
group. HBeAg expression has been associated with a statistically 
signiﬁ  cantly increased risk of HCC, probably because sustained 
HBV replication leads to chronic necroinﬂ  ammatory hepatic dis-
eases, which often result in hepatocarcinogenesis (  5  ,  6  ). Although 
the Precore mutation G1896A also affects HBeAg expression 
(  3  ,  4  ), it has no appreciable effect on the replication capacity of the 
virus in cell culture (  64  ). A1762T/G1764A increases viral replica-
tion (  65  ); moreover, A1762T/G1764A + T1753V mutants show 
enhanced viral replication in cell culture (  64  ,  66  ), indicating that 
A1762T/G1764A alone or in combination with T1753V may be 
associated with high serum viral load in patients. HBV viral load is 
both a risk factor for HCC and a factor associated with HCC 
prognosis (  5  ,  11  ). On the basis of these data, we speculate that 
HBeAg and C1653T, T1753V, and A1762T/G1764A may play a 
synergistic role in hepatocarcinogenesis. 
  HBV genotype is associated with the risk of HCC (  8    –    11  ). One 
possible reason for this association is that HBV mutations may be 
more common among some HBV genotypes than among others. 
To examine this possibility, we stratiﬁ  ed the pooled data into HBV 
genotype B  –   or HBV genotype C  –  matched groups. The highest 
summary odds ratio for PreS mutations was found in the patients 
infected with genotype C, whereas the highest summary odds ratio 
for A1762T/G1764A mutations was found in those infected with 
genotype B. C1653T, T1753V, and A1762T/G1764A mutations 
in HBV C1 and/or C2 were statistically signiﬁ  cantly associated 
with an increased risk of HCC (  Table 3  ). HBV genotype B is asso-
ciated with the early onset of HCC, whereas HBV genotype C is 
associated with development of HCC at older ages (  8    –    10  ). 
A1762T/G1764A is frequently detected approximately 10 years 
before the diagnosis of HCC (  15  ,  34  ,  36  ,  40  ,  46  ,  49  ,  52  ). These ﬁ  nd-
ings together with our combined mutation data suggest that 
A1762T/G1764A is an early event in hepatocarcinogenesis, 
whereas PreS mutations, C1653T, T1753V, and combined muta-
tions are late events. 
  An important ﬁ  nding from this meta-analysis is that PreS muta-
tions, C1653T, T1753V, and A1762T/G1764A are increasingly 
more prevalent as chronic HBV infection progresses from the 
asymptomatic HBsAg carrier state to liver cirrhosis or HCC, indi-
cating that these mutations accumulate before the diagnosis of 
HCC. This ﬁ  nding suggests that these HBV mutations may serve as 
useful biomarkers for predicting the clinical outcomes of patients 
with chronic hepatitis B, especially with regard to predicting 
whether they will develop HCC. A1762T/G1764A was shown to be 
a valuable biomarker for identifying a subset of male HBsAg carriers 
who were at extremely high risk of HCC in a prospective study (  67  ). 
Because A1762T/G1764A was the most common mutation that was 
statistically signiﬁ  cantly associated with a poor prognosis of HBV 
chronic infection (  Figure 4  ), we compared the frequencies of 
A1762T/G1764A-based combined mutations between the patients 
with and without HCC. We found that A1762T/G1764A-based 
combined mutations were more frequent in patients with HCC 
than in those without HCC. We then examined the potential value 
of each mutation or combined HBV mutations for the prediction of 
HCC. We found that PreS, C1653T, and C1653T + T1753V 
mutations and A1762T/G1764A-based combined mutations had 
high speciﬁ  city for the prediction of HCC. A1762T/G1764A com-
bined with other mutations within EnhII/BCP was more speciﬁ  c for 
HCC than A1762T/G1764A alone, indicating that the combined 
mutations increased the risk of HCC in an additive or synergistic 
fashion. Because A1762T/G1764A was increasingly more prevalent 
as chronic HBV infection progressed from the asymptomatic 
HBsAg carrier state to liver cirrhosis or HCC, the predictive value 
of this mutation on HBV-induced HCC may be underestimated in 
the three cohort studies (  48  ,  49  ,  52  ) and the six nested case  –  control 
studies (  15  ,  29  ,  34  ,  36  ,  40  ,  46  ) included in this meta-analysis because 
mutation data in the cohort and nested case  –  control studies are 
recorded at the beginning of cohort establishment. 
  To elucidate if speciﬁ  c PreS mutations (deletion or point muta-
tions) were associated with an increased risk of HCC, we ﬁ  rst com-
pared the frequencies of deleted portions in the PreS region between 
HBV-infected patients with and without HCC. We found that the 
5  ′  -terminal half of PreS2 (nucleotides 3206  –  60) was the most fre-
quently deleted portion of the PreS region in the patients with and 
without HCC but that there was no statistically signiﬁ  cant differ-
ence in the frequency of this deletion between the patients with and 
without HCC. We then investigated the frequencies of point muta-
tions at the promoter sites of PreS1 and PreS2 using data from 695 
HBV-infected patients with and without HCC. We found that 
mutations at the promoter sites of PreS1 and PreS2 were statistically 
signiﬁ  cantly associated with an increased risk of HCC. However, 
the diagnostic or predictive value of mutations at the promoter sites 
of PreS1 and PreS2 for HCC is limited because the frequencies 
of these mutations in the patients with HCC were low (PreS1 
promoter mutation, 19.7%; PreS2 promoter mutation, 15.3%). 
  It is biologically plausible that PreS mutations, C1653T, T1753V, 
and A1762T/G1764A could contribute to the risk of HCC. PreS 
mutations may lead to a lack of effective immunity against HBV by 
altering the immune response elicited by T and B cells (  3  ,  45  ). PreS 
deletions decrease the expression of middle and small surface 
proteins of HBV, resulting in intracellular accumulation of HBV 
surface proteins and viral particles, which may contribute to 
hepatocarcinogenesis by inducing endoplasmic reticulum stress and 
oxidative DNA damage (  3  ,  19  ,  45  ). A number of   trans  -regulating 
nuclear factors such as CCAAT/enhancer-binding protein     , the 
ubiquitous transcription factor Sp1, and hepatocyte nuclear factor 4 
bind HBV at nucleotides 1653, 1753, and/or 1762/1764 (  3  ,  19  ), and 
these HBV sites overlap with the X gene (  3  ,  4  ). C1653T, T1753V, 
and A1762T/G1764A may alter the binding ability of these nuclear 
factors and may also lead to amino acid alterations of X protein, 1080   Articles | JNCI  Vol. 101, Issue 15  |  August 5, 2009
both of which could contribute to hepatocarcinogenesis (  3  ,  4  ,  19  ,  45  ). 
It is possible that such alterations in the X protein could transacti-
vate oncogenes responsible for the development of HCC or that 
transactivators encoded by some oncogenes select the speciﬁ  c HBV 
mutations during HBV-induced hepatocarcinogenesis. 
  HBV mutations described in this study might be useful bio-
markers for the prevention and control of HBV-associated HCC 
because the non-HCC patients infected with HBV with mutations 
might be more likely to develop HCC than those infected with 
HBV without these mutations. Because chronic HBV infection is 
one of the major risk factors of HCC, antiviral therapy may be for 
a way to prevent HBV-induced HCC (  68  ). However, unselected 
and continuous antiviral treatment increases the possibility of drug 
resistance as well as the burden to limited medical resources in the 
developing world. We suggest that PreS mutations, C1653T, 
T1753V, and A1762T/G1764A, alone or in combination, could be 
used as potential markers to identify HBV-infected patients who 
should receive antiviral treatment. 
  This study has several potential limitations. First, the possibil-
ity of information and selection biases and unidentiﬁ  ed confound-
ers cannot be completely excluded because all of the included 
studies were observational. Second, HBV mutation data were not 
available for all participants because HBV DNA could not be 
efﬁ  ciently ampliﬁ  ed by polymerase chain reaction if the viral load 
was below the detection limit. Thus, a selection bias may have 
been introduced because HBV mutation data were more likely to 
be obtained from the participants with high viral load than from 
those with low viral load. Third, only six HBV mutations were 
included in this analysis. Other mutations that have been shown 
to be statistically signiﬁ  cantly associated with the risk of HCC 
(  14  ,  46  ), such as those at T31C, T53C, G1613A, A1703G, 
G1719T, C1726A, and G1730C, were not included because few 
patients had these mutations. Fourth, most studies included in 
this meta-analysis were conducted in Eastern Asia, where HBV 
genotypes C and B are endemic. Thus, our ﬁ  ndings may not be 
generalizable to populations that are infected with other HBV 
genotypes. Fifth, we restricted our search strategy to articles pub-
lished in English or Chinese. Articles with potentially high-quality 
data that were published in other languages were not included 
because of anticipated difﬁ  culties in obtaining accurate medical 
translation. 
  In conclusion, we found that PreS mutations, C1653T, 
T1753V, and A1762T/G1764A are associated with an increased 
risk of HCC. The frequencies of these mutations increase as 
chronic HBV infection progresses from the asymptomatic HBsAg 
carrier state to liver cirrhosis and HCC. Frequent examination of 
patients with chronic HBV infections for the presence of these 
mutations may be useful for identifying which patients require 
preventive antiviral treatment and for the prediction of HCC. 
Future studies should focus on interactions of these HBV muta-
tions with host factors, as well as the development of high-
throughput methods for the detection of HBV mutations for the 
prediction of HCC.   
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